On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.
Since the announcement as of 12 October 2009, the following transactions have been made under the programme:
|
|
Number of
shares |
Average
purchase price |
Transaction value,
DKK |
|
Accumulated, last
announcement |
3,453,000 |
|
1,099,368,013 |
|
12 October 2009 |
65,000 |
322.5260 |
20,964,190 |
|
13 October 2009 |
100,000 |
322.2899 |
32,228,990 |
|
14 October 2009 |
115,000 |
320.4020 |
36,846,230 |
|
15 October 2009 |
70,000 |
322.0800 |
22,545,600 |
|
16 October 2009 |
75,000 |
323.1000 |
24,232,500 |
|
Accumulated under
the programme |
3,878,000 |
|
1,236,185,523 |
With the transactions stated above, Novo Nordisk owns a total of 28,714,808 treasury shares, corresponding to 4.6% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Further information:
|
Media: |
Investors: |
|
|
|
|
Outside North America: |
Outside North America: |
|
Mette Kruse Danielsen |
Mads Veggerby Lausten |
|
Tel: (+45) 4442 3883 |
Tel: (+45) 4443 7919 |
|
|
|
|
|
Kasper Roseeuw Poulsen |
|
|
Tel: (+45) 4442 4471 |
|
|
|
|
|
|
|
In North America: |
In North America: |
|
Sean Clements |
Hans Rommer |
|
Tel: (+1) 609 514 8316 |
Tel: (+1) 609 919 7937 |
Company Announcement no 61/2009
